AMENDMENTS TO THE SPECIFICATION

Please delete the paragraph on page 3, lines 35-37 and replace it with the following amended paragraph:

Figure 4 shows the nucleotide sequence of pJG717 (SEQ ID NO:1) and the corresponding amino acid sequence (SEQ ID NO:3) of the H22-TM coding region within the plasmid. Also shown are restriction sites, as indicated on the pJG717 map shown in Figure 1.

Please delete the paragraph on page 5, lines 1-3 and replace it with the following amended paragraph:

Figure 10 shows the nucleotide sequence of pJG718 (SEQ ID NO:2) and the corresponding amino acid sequence (SEQ ID NO:4) of the A77-TM coding region within the plasmid. Also shown are restriction sites, as indicated on the pJG718 map shown in Figure 9.

Please delete the paragraph on page 20, lines 7-14 and replace it with the following amended paragraph:

In certain embodiments, the V region domains of heavy and light chains can be expressed on the same polypeptide, joined by a flexible linker to form a single-chain Fv fragment, and the scFV gene subsequently cloned into the desired expression vector or phage genome. As generally described in McCafferty et al., *Nature* (1990) 348:552-554, complete V_H and V_L domains of an antibody, joined by a flexible $(Gly_4\text{-}Ser)_3$ linker (SEQ ID NO:5) can be used to produce a single chain antibody which can render the display package separable based on antigen affinity. Isolated scFv antibodies immunoreactive with the antigen can subsequently be formulated into a pharmaceutical preparation for use in the subject method.